Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00957580 · ClinicalTrials.gov registry record · Phase 2
Trial of Pimasertib in Hematological Malignancies
A Phase 2 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT00957580 is a Phase 2 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 81 participants.
The verdict
NCT00957580, a Phase 2 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
This is an open-label, multi-center, dose-escalation trial of pimasertib (MSC1936369B) in blood and bone marrow cancers. The trial will be conducted in two parts: Part 1 (safety run-in period): Will determine the maximum tolerated dose (MTD) of the study drug in subjects with advanced hematological malignancies. Part 2: Will assess the anti-leukemic activity of the study drug in older subjects with newly diagnosed poor prognosis acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy.
Interventions
- DRUG Pimasertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2009-09-30 |
| Est. Completion | 2012-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00957580
The ClinicalTrials.gov registry entry for NCT00957580 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pimasertib is the first listed.
NCT00957580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00957580 about?
NCT00957580 is a clinical study titled "Trial of Pimasertib in Hematological Malignancies". This is an open-label, multi-center, dose-escalation trial of pimasertib (MSC1936369B) in blood and bone marrow cancers. The trial will be conducted in two parts: Part 1 (safety run-in period): Will determine the maximum tolerated dose (MTD) of the study drug in subjects with advanced hematological...
What is the current status of trial NCT00957580?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2009-09-30. Estimated completion is 2012-12-31.
What interventions are being tested in trial NCT00957580?
The interventions under investigation include: Pimasertib (DRUG).
Who is sponsoring clinical trial NCT00957580?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.